Risant Health completes acquisition of Geisinger
April 4, 2024—Risant Health has completed its acquisition of Geisinger, the first health system to join Risant in expanding access to value-based care in communities across the country.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Abbott TBI cartridge cleared for use with whole blood
April 3, 2024—Abbott’s i-Stat TBI cartridge has received FDA clearance for use with whole blood, allowing clinicians to help assess patients with suspected concussion at the patient’s bedside.
SpotFire R/ST panel gets 510(k) clearance, CLIA waiver
April 2, 2024—BioMérieux has received FDA 510(k) clearance and CLIA waiver approval for the BioFire SpotFire Respiratory/Sore Throat (R/ST) panel.
FDA approves test to screen for malaria in blood donors
April 1, 2024—Roche announced FDA approval of the Cobas Malaria test, a qualitative in vitro nucleic acid screening test for the direct detection of Plasmodium RNA and DNA in whole blood samples from individual human donors.
Next-gen StatStrip glucose system gets 510(k) clearance
March 29, 2024—Nova Biomedical announced the U.S. launch of its 510(k)-cleared, next-generation StatStrip Glucose Hospital meter system.
StatLab acquires Poly Scientific R&D
March 28, 2024—StatLab Medical Products announced the acquisition of Poly Scientific R&D, a manufacturer and supplier of pathology stains, reagents, and paraffin for anatomic pathology laboratories.
Labcorp acquires assets of BioReference lab testing business
March 28, 2024—Labcorp and Opko Health announced they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of Opko, for $237.5 million.
De novo classification granted for plasma cell enrichment kit
March 27, 2024—Stemcell Technologies announced that the FDA has granted de novo classification for its immunomagnetic plasma cell enrichment kit.
Gestalt demos new PathFlow features at USCAP meeting
March 26, 2024—Gestalt Diagnostics announce the launch of its AI Algorithm Evaluator, a new tool within the company’s PathFlow digital pathology platform.
Bayer, Thermo Fisher to develop NGS CDx assays
March 21, 2024—Bayer and Thermo Fisher Scientific announced that they will develop next-generation sequencing–based companion diagnostic assays to help identify patients who may benefit from Bayer’s precision cancer therapies.